On Oct 04, major Wall Street analysts update their ratings for $Humana (HUM.US)$, with price targets ranging from $250 to $364.
Barclays analyst Andrew Mok CFA downgrades to a hold rating, and maintains the target price at $364.
UBS analyst Kevin Caliendo maintains with a hold rating, and adjusts the target price from $370 to $250.
Deutsche Bank analyst George Hill maintains with a hold rating, and sets the target price at $250.
Oppenheimer analyst Michael Wiederhorn maintains with a buy rating, and adjusts the target price from $400 to $280.
Piper Sandler analyst Jessica Tassan downgrades to a hold rating, and adjusts the target price from $392 to $274.
Furthermore, according to the comprehensive report, the opinions of $Humana (HUM.US)$'s main analysts recently are as follows:
The performance of Humana is anticipated to hinge on the outcome of their appeal with CMS concerning the reported decline in the 2025 Star ratings for payment year 2026. However, it is considered 'unlikely' that a resolution will be reached before the commencement of open enrollment.
For 2025, Humana's coverage for members under bonus-qualified plans is expected to decrease to 25%, a notable reduction from the 94% coverage in 2024. This shift is seen as falling short of investor expectations and presents a considerable risk concern for the company's financial performance in 2026.
The firm has adjusted its outlook on Humana following the recent Star rating call, noting that the company is close to achieving the critical 4-Star threshold in several plans, which could be pivotal pending the outcome of an appeal. Despite potential setbacks, there's optimism around the company's ability to make a comeback next year. Humana's management is exploring various options to mitigate challenges, although it is premature to provide detailed guidance. The recent updates have cast doubt on the company's ability to meet its 3% margin goal by 2027.
Here are the latest investment ratings and price targets for $Humana (HUM.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
